Approval · Notice of Compliance 9015 · 2007
TRUVADA: Notice of Compliance 9015
Issued September 11, 2007
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 9015
- Date
- September 11, 2007
- Company
- Gilead Sciences, Inc.Foster City, California, United States
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Streamlined and altered position of some adverse events in warnings and precautions and adverse events sections of product monograph. addition of drug interaction information with respect to coadministration of tenofovir disoproxil fumarate (tdf) with didanosine (ddl). updates added to the postmarketing adverse drug reaction section of product monograph
- Therapeutic class
- Antiretroviral agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TRUVADA | Not yet assigned | — |
Medicinal ingredients
- EMTRICITABINE 200 MG per TAB
- TENOFOVIR DISOPROXIL FUMARATE 300 MG per TAB